Christopher R Cabanski
Overview
Explore the profile of Christopher R Cabanski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1360
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Galsky M, Autio K, Cabanski C, Wentzel K, Graff J, Friedlander T, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39964352
Purpose: Current immune checkpoint therapies offer limited benefits for metastatic castration-resistant prostate cancer (mCRPC). Novel combinations may enhance immunotherapy efficacy. Patients And Methods: We conducted an open-label, non-comparative platform trial...
2.
Tsimberidou A, Alayli F, Okrah K, Drakaki A, Khalil D, Kummar S, et al.
J Exp Med
. 2024 Aug;
221(10).
PMID: 39190534
Identifying pan-tumor biomarkers that predict responses to immune checkpoint inhibitors (ICI) is critically needed. In the AMADEUS clinical trial (NCT03651271), patients with various advanced solid tumors were assessed for changes...
3.
Till J, McDaniel L, Chang C, Long Q, Pfeiffer S, Lyman J, et al.
Nat Commun
. 2024 Jul;
15(1):5763.
PMID: 38982051
While high circulating tumor DNA (ctDNA) levels are associated with poor survival for multiple cancers, variant-specific differences in the association of ctDNA levels and survival have not been examined. Here...
4.
Glitza I, Seo Y, Spencer C, Wortman J, Burton E, Alayli F, et al.
Cancer Discov
. 2024 Apr;
14(7):1161-1175.
PMID: 38588588
Gut-microbiota modulation shows promise in improving immune-checkpoint blockade (ICB) response; however, precision biomarker-driven, placebo-controlled trials are lacking. We performed a multicenter, randomized placebo-controlled, biomarker-stratified phase I trial in patients with...
5.
Padron L, Maurer D, OHara M, OReilly E, Wolff R, Wainberg Z, et al.
Nat Med
. 2022 Jun;
28(6):1167-1177.
PMID: 35662283
Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). We conducted a randomized phase 2 trial evaluating...
6.
Friedman C, Spencer C, Cabanski C, Panageas K, Wells D, Ribas A, et al.
J Immunother Cancer
. 2022 Jan;
10(1).
PMID: 35074903
Background: There are no validated biomarkers that can aid clinicians in selecting who would best benefit from anticytotoxic T lymphocyte-associated antigen 4 monotherapy versus combination checkpoint blockade in patients with...
7.
Cheung D, Fong A, Ding H, Cabanski C, Wang J, Chen Y, et al.
Pulm Pharmacol Ther
. 2021 Jun;
69:102051.
PMID: 34166834
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease. Although anti-fibrotic treatments, such as pirfenidone, are available that reduce the rate of disease progression, these medications have limitations...
8.
OHara M, OReilly E, Varadhachary G, Wolff R, Wainberg Z, Ko A, et al.
Lancet Oncol
. 2021 Jan;
22(1):118-131.
PMID: 33387490
Background: Standard chemotherapy remains inadequate in metastatic pancreatic adenocarcinoma. Combining an agonistic CD40 monoclonal antibody with chemotherapy induces T-cell-dependent tumour regression in mice and improves survival. In this study, we...
9.
Dang H, Krasnick B, White B, Grossman J, Strand M, Zhang J, et al.
Sci Adv
. 2020 Jun;
6(24):eaay9691.
PMID: 32577507
Tumor heterogeneity and evolution drive treatment resistance in metastatic colorectal cancer (mCRC). Patient-derived xenografts (PDXs) can model mCRC biology; however, their ability to accurately mimic human tumor heterogeneity is unclear....
10.
Silva-Fisher J, Dang H, White N, Strand M, Krasnick B, Rozycki E, et al.
Nat Commun
. 2020 May;
11(1):2156.
PMID: 32358485
Colorectal cancer (CRC) is the most common gastrointestinal malignancy in the U.S.A. and approximately 50% of patients develop metastatic disease (mCRC). Despite our understanding of long non-coding RNAs (lncRNAs) in...